-transparent.png){kind=logo}
The synthetic growth hormone release inhibiting hormone (GH-RIH) was conjugated with human serum globulin using glutaraldehyde and administered to rabbits. An antiserum thus generated 70% of 125I-Tyr1-GH-RIH. The binding was inhibited by unlabelled GH-RIH and the inhibition was dose-related, enabling us to establish a radioimmunoassay method for GH-RIH. The minimum detectable dose was 4 pg. A linearity was demonstrated for immunoreactive GH-RIH of extracts of rat and pig hypothalami, indicating that they contained substance(s) indistinguishable from GH-RIH. Various hypothalamic and pituitary hormones did not interfere with the radioimmunoassay, but considerable cross-reaction was observed for linear GH-RIH and the ring portion of GIH-RIH, suggesting that the antigenic determinant involved the amino acid sequence from position 3-14 of GH-RIH or part of it. Plasma protein appears to contain substance(s) immunologically indistinguishable from GH-RIH or to interfere, in a nonspecific manner, with the radioimmunoassay system for GH-RIH.
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
November 1992,
Endocrinology,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
January 1976,
Current topics in molecular endocrinology,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
November 1976,
Clinical endocrinology,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
June 2013,
General and comparative endocrinology,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
January 2000,
Novartis Foundation symposium,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
April 1978,
Gut,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
September 1988,
Psychiatry research,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
August 1989,
The Journal of clinical endocrinology and metabolism,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
March 1977,
Clinics in endocrinology and metabolism,
A Arimura, and
H Sato, and
D H Coy, and
A V Schally
June 1974,
Lancet (London, England),
